Tyche Industries Ltd
Incorporated in 1998, Tyche Industries Ltd
does manufacturing of active pharmaceutical ingredients[1]
- Market Cap ₹ 142 Cr.
- Current Price ₹ 139
- High / Low ₹ 224 / 129
- Stock P/E 11.7
- Book Value ₹ 133
- Dividend Yield 2.16 %
- ROCE 12.7 %
- ROE 9.41 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.04 times its book value
Cons
- The company has delivered a poor sales growth of -2.34% over past five years.
- Company has a low return on equity of 10.7% over last 3 years.
- Earnings include an other income of Rs.7.66 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
104 | 64 | 54 | 43 | 52 | 54 | 74 | 78 | 62 | 75 | 70 | 65 | 63 | |
94 | 57 | 51 | 37 | 43 | 45 | 52 | 54 | 51 | 59 | 57 | 54 | 52 | |
Operating Profit | 11 | 7 | 3 | 6 | 9 | 9 | 21 | 25 | 11 | 16 | 13 | 11 | 11 |
OPM % | 10% | 11% | 5% | 14% | 18% | 17% | 29% | 32% | 18% | 21% | 18% | 17% | 17% |
0 | 0 | 2 | 2 | 2 | 3 | 4 | 4 | 3 | 5 | 6 | 7 | 8 | |
Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Profit before tax | 8 | 3 | 3 | 6 | 9 | 10 | 23 | 27 | 13 | 19 | 17 | 17 | 16 |
Tax % | 32% | 33% | 4% | 48% | 34% | 27% | 25% | 25% | 26% | 26% | 26% | 26% | |
6 | 2 | 2 | 3 | 6 | 7 | 18 | 20 | 9 | 14 | 12 | 12 | 12 | |
EPS in Rs | 5.39 | 1.88 | 2.41 | 3.00 | 5.72 | 6.98 | 17.13 | 19.49 | 9.10 | 13.82 | 11.94 | 12.11 | 11.80 |
Dividend Payout % | 9% | 26% | 21% | 17% | 9% | 7% | 0% | 5% | 16% | 0% | 21% | 25% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | -2% |
3 Years: | 2% |
TTM: | -8% |
Compounded Profit Growth | |
---|---|
10 Years: | 20% |
5 Years: | -7% |
3 Years: | 8% |
TTM: | -1% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | -12% |
3 Years: | 0% |
1 Year: | -25% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 13% |
3 Years: | 11% |
Last Year: | 9% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 33 | 34 | 35 | 38 | 43 | 50 | 67 | 86 | 94 | 107 | 116 | 126 |
11 | 9 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
19 | 12 | 11 | 13 | 14 | 14 | 18 | 21 | 16 | 20 | 8 | 11 | |
Total Liabilities | 74 | 64 | 67 | 61 | 67 | 74 | 95 | 117 | 120 | 137 | 135 | 147 |
33 | 29 | 28 | 27 | 20 | 19 | 18 | 18 | 17 | 17 | 18 | 16 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
40 | 35 | 39 | 34 | 47 | 55 | 77 | 98 | 104 | 120 | 117 | 131 | |
Total Assets | 74 | 64 | 67 | 61 | 67 | 74 | 95 | 117 | 120 | 137 | 135 | 147 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
9 | 2 | 12 | 11 | 5 | 4 | 15 | 15 | 4 | 6 | 8 | 9 | |
-6 | -1 | -1 | 1 | 6 | 1 | 2 | 0 | 3 | -3 | 4 | -1 | |
0 | -3 | 2 | -11 | -1 | -0 | -1 | -1 | -1 | -2 | -2 | -3 | |
Net Cash Flow | 3 | -2 | 12 | 1 | 11 | 4 | 17 | 15 | 7 | 2 | 10 | 5 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 46 | 91 | 107 | 81 | 68 | 69 | 64 | 80 | 96 | 107 | 100 | 95 |
Inventory Days | 91 | 138 | 68 | 84 | 85 | 123 | 122 | 148 | 148 | 195 | 157 | 245 |
Days Payable | 68 | 76 | 93 | 130 | 87 | 96 | 91 | 93 | 78 | 134 | 48 | 85 |
Cash Conversion Cycle | 69 | 153 | 82 | 34 | 67 | 96 | 94 | 135 | 167 | 168 | 210 | 255 |
Working Capital Days | 35 | 77 | 21 | 60 | 67 | 87 | 77 | 83 | 121 | 129 | 144 | 151 |
ROCE % | 18% | 7% | 5% | 12% | 18% | 17% | 34% | 32% | 13% | 17% | 14% | 13% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Dividend Updates
14 Oct - Declared 30% dividend (Rs 3.00/share); payment started 10 Oct 2025; record date 19 Sep 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Oct - Compliance Certificate under Regulation 74 (5) of SEBI (D&P) Regulations, 2018 for the quarter ended September 30, 2025.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
1 Oct - AGM 30 Sep 2025: all resolutions passed; 30% dividend (Rs.3); Sandeep Gokaraju appointed MD.
-
Announcement under Regulation 30 (LODR)-Change in Management
30 Sep - AGM 30 Sep 2025 approved Sandeep Gokaraju as MD, Satya Uppalapati as Executive Director; other board changes.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
30 Sep - Sandeep Gokaraju appointed MD five-year term from 05 Sep 2025; other director changes on 30 Sep 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
Company is a manufacturer and exporter of APIs, Intermediates and Nutraceuticals. It is one of the largest Indian manufacturers of Glucosamine Hydrochloride and corresponding sodium and potassium salts which are mainly exported to USA and Europe